{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:21:35Z","timestamp":1765887695907},"reference-count":7,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Scattergrams between vancomycin and telavancin demonstrated susceptibility agreement rates of 99.96, 99.65, and 100.00% for\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            ,\n            <jats:named-content content-type=\"genus-species\">Enterococcus faecalis<\/jats:named-content>\n            , and streptococci, respectively. A single very major error was obtained against\n            <jats:named-content content-type=\"genus-species\">E. faecalis<\/jats:named-content>\n            , while vancomycin-intermediate\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            (VISA) and vancomycin-resistant and teicoplanin-susceptible (VanB phenotype)\n            <jats:named-content content-type=\"genus-species\">E. faecalis<\/jats:named-content>\n            were responsible for major and minor errors. These results support the use of vancomycin to infer telavancin susceptibility among indicated pathogens, except VISA, which should be tested for telavancin susceptibility.\n          <\/jats:p>","DOI":"10.1128\/jcm.00611-15","type":"journal-article","created":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T12:54:13Z","timestamp":1432817653000},"page":"2727-2730","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin"],"prefix":"10.1128","volume":"53","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04052-14"},{"key":"e_1_3_2_3_2","volume-title":"Vibativ (telavancin) for injection, for intravenous use","author":"Theravance Biopharma, Inc","year":"2014","unstructured":"Theravance Biopharma, Inc. 2014. Vibativ (telavancin) for injection, for intravenous use. Theravance Biopharma, Inc., South San Francisco, CA. http:\/\/www.vibativ.com\/docs\/VIBATIV_PI_Final.pdf."},{"key":"e_1_3_2_4_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA. http:\/\/www.ncipd.org\/UserFiles\/CLSI_M100-S24.pdf."},{"key":"e_1_3_2_5_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0","author":"EUCAST","year":"2014","unstructured":"EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. European Committee on Antimicrobial Susceptibility Testing, V\u00e4xj\u00f6, Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_4.0.pdf."},{"key":"e_1_3_2_6_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20149th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA. http:\/\/antimicrobianos.com.ar\/ATB\/wp-content\/uploads\/2012\/11\/03-CLSI-M07-A9-2012.pdf.","edition":"9"},{"key":"e_1_3_2_7_2","volume-title":"CLSI document M23-A3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters, 3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.12.011"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00611-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00611-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:22:53Z","timestamp":1646482973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00611-15"}},"subtitle":[],"editor":[{"given":"S. S.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1128\/JCM.00611-15"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00611-15","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"2015-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}